NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) announced today that it has completed its acquisition of Icagen, Inc., through the merger of its wholly owned subsidiary, Eclipse Acquisition Corp., with and into Icagen. Icagen is now a wholly-owned subsidiary of Pfizer. Under the terms of the transaction, each issued and outstanding share of Icagen common stock has been converted into the right to receive $6.00 in cash, without interest thereon, and less any applicable withholding and transfer

NEW YORK--(BUSINESS WIRE)--The board of directors of Pfizer Inc. (NYSE: PFE) today declared a 20-cent fourth-quarter 2011 dividend on the company’s common stock, payable December 6, 2011, to shareholders of record at the close of business on November 11, 2011. The fourth-quarter 2011 cash dividend will be the 292nd consecutive quarterly dividend paid by Pfizer.

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) announced today that the European Commission has approved the Company’s pneumococcal conjugate vaccine, Prevenar 13* (pneumococcal polysaccharide conjugate vaccine [13-valent, adsorbed]), for active immunization for the prevention of vaccine-type invasive disease caused by Streptococcus pneumoniae in adults aged 50 years and older. “Prevenar 13, the first and only pneumococcal conjugate vaccine approved by the European Commission for use in adul

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) announced today that it has established a research collaboration with Medco Health Solutions, Inc. (NYSE: MHS) and its wholly owned subsidiary, United BioSource Corporation (UBC), aimed at more effectively matching patients with treatments that will benefit them the most, thereby improving patient outcomes. The collaboration is intended to enhance Pfizer’s precision medicine approach, which integrates genomic and phenotypic information, to help

MADISON, N.J.--(BUSINESS WIRE)--This week, Robitussin® marked the start of another cold and flu season by shaking up the most contagious months of the calendar year for America’s “sick but can’t stop” sufferers with the launch of the Simple Acts of Relief program. To kick-off the launch of the program, Robitussin® has teamed up with iconic Olympic and World ice skating champion and sports commentator, Peggy Fleming. As the “simplest” act of relief, the makers of Robitussin® and Ms. Fleming are m

GENEVA--(BUSINESS WIRE)--The World Intellectual Property Organization (WIPO), in an unprecedented collaboration with leading pharmaceutical companies and BIO Ventures for Global Health (BVGH), launched today WIPO Re:Search, a new consortium where public and private sector organizations share valuable intellectual property (IP) and expertise with the global health research community to promote development of new drugs, vaccines, and diagnostics to treat neglected tropical diseases, malaria, and t

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. invites investors and the general public to view and listen to a webcast of a presentation by Pfizer’s specialty care leadership team at an analyst and investor meeting on Sunday, November 6, 2011 at 6:30 p.m. Central Standard Time, in connection with the annual meeting of the American College of Rheumatology (ACR). To view and listen to the webcast, visit our web site at www.pfizer.com and click on the “Pfizer Analyst and Investor Meeting at ACR” link in T

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) announced today that additional data from several clinical studies of Prevnar 13®* (Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]) conducted in adults 50 years and older will be presented during the 49th Annual Meeting of the Infectious Diseases Society of America (IDSA), which is being held Oct. 20-23, 2011, in Boston, Mass. The data from these studies provide support for the pending regulatory applications for the use of

NEW YORK--(BUSINESS WIRE)--Pfizer Animal Health and The Resource Foundation announced today the expansion of a comprehensive education and training program to increase the capacity, productivity and quality of life of rural farmers in eight Latin American countries. Plans call for tailoring the program to the needs of rural communities in India. The agreement was guided by results of a decade-long collaboration also announced today. Pfizer Animal Health and the Pfizer Foundation have committed $

LOUISVILLE, Ky. & NEW YORK--(BUSINESS WIRE)--Humana Inc. (NYSE: HUM) and Pfizer Inc. (NYSE: PFE) today announced a five-year research partnership to explore new ideas and ways to improve the quality, outcomes and costs of the health care delivery system for senior citizens and other populations. Humana, one of the nation’s largest health care companies, and Pfizer, the world’s largest biopharmaceutical company, will bring together researchers and health care experts from both organizations to st